Patient preferences in choosing anti-TNF therapies-R1 [4]

Rheumatology

Volumn 45, Issue 12, 2006, Pages 1575-1576

  Williams, E L ^a   Edwards, C J ^a  

^a UNIVERSITY HOSPITAL SOUTHAMPTON NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; DISEASE MODIFYING ANTIRHEUMATIC DRUG; RITUXIMAB; TUMOR NECROSIS FACTOR ANTIBODY;

CLINICAL PRACTICE; COMMUNITY CARE; CONTROLLED STUDY; DRUG ADMINISTRATION ROUTE; DRUG EFFICACY; DRUG PREFERENCE; HOME CARE; HUMAN; LETTER; LICENSING; MAJOR CLINICAL STUDY; OUTPATIENT CARE; PATIENT ATTITUDE; PATIENT COMPLIANCE; PATIENT SATISFACTION; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; TREATMENT DURATION; UNITED KINGDOM;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INJECTIONS; MALE; PATIENT SATISFACTION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33751413085     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kel369     Document Type: Letter

References (6)

1. Genovese MC, Becker JC, Schiff M et al. Abatacept for rheumatoid arthritis refractory to TNF alpha inhibition. N Eng J Med 2005;353:1114-23.
2. Voll RE, Kalden JR. Do we need new treatment that goes beyond TNF blockers for rheumatoid arthritis? Ann NY Acad Sci 2005;1051:799-810.
3. Kennedy T, McCabe C, Struthers G et al. BSR guidelines on standards of care for persons with rheumatoid arthritis. Rheumatology 2005;44:553-6.
4. Bennett SP, Sawyer S, Baker A, Arden NK, Edwards CJ. Patient preferences in choosing anti-TNF therapies. Abstract presented at BSR May 2005.
5. Department of Health. Our health, our care, our say: A new direction for community services. White Paper, Department of Health 30/01/06 ISBN: 0101673728.
6. Edwards CJ, Arden NK, Fisher D et al. The changing use of disease-modifying anti-rheumatic drugs in individuals with rheumatoid arthritis from the United Kingdom General Practice Research Database. Rheumatology 2005;44:1394-8.